Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab

Cardio-Oncology

Table 3 Area under the curve estimates for the prediction of cardiotoxicity risk using traditional risk factors and epigenetic age acceleration metrics

Model components	AUC	95% CI		P-diff
Risk factors only	0.749	0.659	0.840	------
Risk factors + rs776746	0.764	0.677	0.852	0.24
Risk factors + Hannum AgeAccel	0.784	0.701	0.867	0.08
Risk factors + Horvath AgeAccel	0.781	0.679	0.864	0.12
Risk factors + Hovath Skin and Blood AgeAccel	0.791	0.709	0.873	0.04
Risk factors + three AgeAccel metrics	0.794	0.712	0.875	0.04
Risk factors + three AgeAccel metrics + rs776746	0.795	0.714	0.877	0.05

Risk factors include age at diagnosis, smoking status, BMI category, CVD medication use, prevalence of chronic conditions at diagnosis, prior history of cancer, history of chemotherapy, and treatment with anthracyclines. P-diff represents the p-value for the difference between the risk factor-only model

ISSN: 2057-3804